Summary of COVID-19 pomotrelvir studies

1. Borroto-Esoda et al., SARS-CoV-2 viral dynamics in a placebo-controlled phase 2 study of patients infected with the SARS-CoV-2 Omicron variant and treated with pomotrelvir

230 patient pomotrelvir early treatment RCT: 1% worse recovery (p=1) and 252% worse results (p=0.1).
RCT 242 symptomatic outpatients showing no significant difference in viral clearance or symptom resolution with pomotrelvir treatment initiated within 5 days of symptom onset. Based on the description provided it is not clear why the number of censored patients changes in the treatment group between the 5, 12, and 14 symptom results. The event count and percentage reported for the 12 symptom result do not match. Authors also compare viral clearance based on infectious virus assay (IVA), RAT, and PCR, which shows that PCR/RAT results are often positive when IVA shows no infectious virus.
Feb 2024, Microbiology Spectrum, https://journals.asm.org/doi/10.1128/spectrum.02980-23, https://c19p.org/borrotoesoda

Submit Corrections or Updates

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0